Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: The INtegrilin plus STenting to Avoid myocardial Necrosis Trial

American Heart Journal

Volumn 163, Issue 5, 2012, Pages 835.e1-835.e7

  Biondi Zoccai, Giuseppe ^a   Valgimigli, Marco ^b   Margheri, Massimo ^c   Marzocchi, Antonio ^d   Lettieri, Corrado ^e   Stabile, Amerigo ^f   Petronio, A Sonia ^g   Binetti, Giorgio ^h   Bolognese, Leonardo ⁱ   Bellone, Pietro ^j   Sardella, Gennaro ^k   Contarini, Marco ^l   Sheiban, Imad ^m   Marra, Sebastiano ⁿ   Piscione, Federico ^o   Romeo, Francesco ^p   Colombo, Antonio ^q   Sangiorgi, Giuseppe ^p  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c Ravenna Hospital   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e CARLO POMA HOSPITAL   (Italy)

^f ARNAS   (Italy)

^g UNIVERSITY OF PISA   (Italy)

^h SAN SALVATORE HOSPITAL   (Italy)

ⁱ IRCCS POLICLINICO SAN DONATO   (Italy)

^j San Paolo Hospital   (Italy)

^k POLICLINICO UMBERTO I   (Italy)

^l Umberto I Hospital   (Italy)

^m UNIVERSITY OF TURIN   (Italy)

ⁿ MOLINETTE HOSPITAL   (Italy)

^o UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^p UNIVERSITY OF ROME TOR VERGATA   (Italy)

^q SAN RAFFAELE HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; CLOPIDOGREL; CREATINE KINASE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; HEPARIN; PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; RISK FACTOR; SINGLE BLIND PROCEDURE;

EID: 84861326668     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.02.009     Document Type: Article

References (28)

1. E. Karvouni, D.G. Katritsis, and J.P. Ioannidis Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions J Am Coll Cardiol 41 2003 26 32 (Pubitemid 36044399)
2. E.J. Topol, D.B. Mark, and A.M. Lincoff Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicenter randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Lancet 354 1999 2019 2024
3. J.C. O'Shea, C.E. Buller, and W.J. Cantor Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention JAMA 287 2002 618 621 (Pubitemid 34252014)
4. A. Kastrati, J. Mehilli, and F.J. Neumann Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial JAMA 295 2006 1531 1538
5. A. Kastrati, J. Mehilli, and H. Schuhlen A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel N Engl J Med 350 2004 232 238 (Pubitemid 38071801)
6. M. Lotrionte, G. Biondi-Zoccai, and P. Agostoni Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention Am J Cardiol 100 2007 1199 1206
7. G.W. Stone, B. Witzenbichler, and G. Guagliumi Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial Lancet 377 2011 2193 2204
8. A. Kastrati, F.J. Neumann, and S. Schulz Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction N Engl J Med 365 2011 1980 1989
9. M. Valgimigli, G. Percoco, and P. Malagutti Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial JAMA 293 2005 2109 2117 (Pubitemid 40617063)
10. M. Valgimigli, G. Campo, and G. Percoco Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial JAMA 299 2008 1788 1799 (Pubitemid 351549970)
11. G.G.L. Biondi-Zoccai, G.M. Sangiorgi, and A. Chieffo Validation of predictors of intraprocedural stent thrombosis in the drug-eluting stent era Am J Cardiol 95 2005 1466 1468 (Pubitemid 40824770)
12. D. Orlic, E. Bonizzoni, and G. Stankovic Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: immediate and mid-term results J Am Coll Cardiol 43 2004 1154 1160 (Pubitemid 38452589)
13. E. Tsagalou, A. Chieffo, and I. Iakovou Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery J Am Coll Cardiol 45 2005 1570 1573 (Pubitemid 40704487)
14. G.G. Biondi-Zoccai, M. Valgimigli, and I. Sheiban A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial J Cardiovasc Med (Hagerstown) 9 2008 957 962
15. G. Biondi-Zoccai, M. Lotrionte, and P. Agostoni Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes Int J Cardiol 150 2011 325 331
16. G.G. Biondi-Zoccai, P. Agostoni, and A. Abbate Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent-controlled trials Int J Cardiol 100 2005 119 123 (Pubitemid 40487945)
17. A. Colombo, P. Hall, and S. Nakamura Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance Circulation 91 1995 1676 1688
18. B. Lengenfelder, S. Stoerk, and L. Boes Long-term reduction of mortality in the 4-year follow up of tirofiban therapy in elective percutaneous coronary interventions (TOPSTAR) trial J Invasive Cardiol 23 2011 128 132
19. P.S. Teirstein, J. Kao, and M. Watkins Impact of platelet glycoprotein IIb/IIIa inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy) Am J Cardiol 96 2005 500 505 (Pubitemid 41135874)
20. M. Valgimigli, G. Campo, and N. de Cesare Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study Circulation 119 2009 3215 3222
21. M. Schiariti, A. Saladini, and D. Cuturello Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention J Cardiovasc Med (Hagerstown) 12 2011 29 36
22. H.S. Gurm, U. Tamhane, and P. Meier A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials Circ Cardiovasc Interv 2 2009 230 236
23. G. De Luca, G. Ucci, and E. Cassetti Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis J Am Coll Cardiol 53 2009 1668 1673
24. A. Akerblom, S.K. James, and M. Koutouzis Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) J Am Coll Cardiol 56 2010 470 475
25. F. Ottani, L. La Vecchia, and M. De Vita Comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention Am J Cardiol 106 2010 167e1 174e1
26. M. Valgimigli, G. Biondi-Zoccai, and M. Tebaldi Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials Eur Heart J 31 2010 35 49
27. U. Zeymer, A. Margenet, and M. Haude Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial J Am Coll Cardiol 56 2010 463 469
28. G.H. Guyatt, E.J. Mills, and D. Elbourne In the era of systematic reviews, does the size of an individual trial still matter PLoS Med 5 2008 e4